# Annex 18-C

## Malaysia

1. Malaysia may, for the purpose of granting protection as specified in **Article
18.50.1 and Article 18.50.2 (Protection of Undisclosed Test or Other Data)** and **Article 18.52.1 (Biologics)**, require an applicant to commence the process of obtaining marketing approval for pharmaceutical products covered under those Articles within 18 months from the date that the product is first granted marketing approval in any country.

2. For greater certainty, the periods of protection referred to in **Article 18.50.1 and Article 18.50.2 (Protection of Undisclosed Test or Other Data)** and **Article 18.52.1 (Biologics)** shall begin on the date of marketing approval of the  pharmaceutical product in Malaysia.


